2019
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 2019, 14: e0220453. PMID: 31369597, PMCID: PMC6675109, DOI: 10.1371/journal.pone.0220453.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotype 3 invasive pneumococcal diseaseHerd protection effectsIPD casesAge groupsPCV13-type invasive pneumococcal diseaseAdult invasive pneumococcal diseaseAdult pneumococcal vaccinationPneumococcal vaccination programAdults 60 yearsVaccine serotypes 4Years of ageAdult age groupsIndirect protection effectPneumococcal vaccinationPneumococcal diseasePolysaccharide vaccineVaccine recommendationsChildhood vaccinationVaccination programVaccine formulationsAdult coverageAdults 60Protection effectSerotype 4Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany
Perniciaro S, Imöhl M, Fitzner C, van der Linden M. Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany. PLOS ONE 2019, 14: e0210278. PMID: 30625215, PMCID: PMC6326516, DOI: 10.1371/journal.pone.0210278.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseVaccine-type invasive pneumococcal diseaseVT invasive pneumococcal diseaseUnvaccinated childrenSerotype distributionPneumococcal diseaseVaccination statusHigher oddsChildhood invasive pneumococcal diseaseDifferent serotype distributionSerotype of infectionVaccine-type serotypesNon-vaccine serotypesDose of vaccineYears of agePCV10 groupPCV13 groupPCV7 groupVaccine recommendationsAdministration scheduleContinued surveillanceProtective effectParticular serotypeInfectionSignificant predictors
2018
Invasive Pneumococcal Disease in Refugee Children, Germany
Perniciaro S, Imöhl M, van der Linden M. Invasive Pneumococcal Disease in Refugee Children, Germany. Emerging Infectious Diseases 2018, 24: 1934-1936. PMID: 30226179, PMCID: PMC6154141, DOI: 10.3201/eid2410.180253.Peer-Reviewed Original Research
2017
Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014
Imöhl M, Fitzner C, Perniciaro S, van der Linden M. Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014. PLOS ONE 2017, 12: e0180757. PMID: 28719668, PMCID: PMC5515411, DOI: 10.1371/journal.pone.0180757.Peer-Reviewed Original ResearchConceptsSuperantigen genesEmm typesNationwide laboratory-based surveillance studyInvasive S. pyogenes infectionInvasive Streptococcus pyogenes diseaseSignificant associationLaboratory-based surveillance studyFrequent clinical manifestationsS. pyogenes infectionCommon emm typesProportion of isolatesClinical manifestationsClinical complicationsEmm 1Peritoneal fluidPyogenes infectionCerebrospinal fluidSurveillance studyEmm 28Synovial fluidEmm 89S. pyogenesType 3SpeJMost isolates
2016
Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Fitzner C, Imöhl M. Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany. PLOS ONE 2016, 11: e0161257. PMID: 27526117, PMCID: PMC4985133, DOI: 10.1371/journal.pone.0161257.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineAdjusted vaccine effectivenessTimeliness of vaccinationVaccine effectivenessPost boosterConjugate vaccinePneumococcal diseaseVaccine-type invasive pneumococcal diseaseType invasive pneumococcal diseaseIndirect cohort methodOverall vaccine effectivenessPneumococcal conjugate vaccinationSpecific vaccine effectivenessNumber of dosesYears of ageResidual casesTime of infectionConjugate vaccinationPCV13 serotypesPCV7 serotypesFirst doseIPD casesUnvaccinated childrenVaccination status
2015
Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLOS ONE 2015, 10: e0131494. PMID: 26132078, PMCID: PMC4488910, DOI: 10.1371/journal.pone.0131494.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenes, BacterialGermanyHeptavalent Pneumococcal Conjugate VaccineHumansImmunization ProgramsImmunologic SurveillanceInfantInfant, NewbornMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesRNA, Ribosomal, 16SSerogroupSerotypingStreptococcus pneumoniaeVaccinationConceptsEarly vaccination periodPneumococcal conjugate vaccinationInvasive pneumococcal diseaseVaccination periodConjugate vaccinationPCV7 serotypesIPD casesPneumococcal diseaseQuellung methodSerotype distributionChildhood pneumococcal conjugate vaccinationNon-vaccinated age groupsAge groupsGerman National Reference CenterPre-vaccination periodSerotype 1Streptococcus pneumoniae isolatesNational Reference CenterMicrobiological diagnostic laboratorySerotype 10AInfant vaccinationVaccine serotypesSerotype 19ASeparate age groupsPneumoniae isolatesIncrease of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infectious Diseases 2015, 15: 207. PMID: 25940580, PMCID: PMC4424534, DOI: 10.1186/s12879-015-0941-9.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePenicillin non-susceptible isolatesNon-PCV13 serotypesNon-susceptible isolatesSerotype 15AVaccination periodSurveillance of IPDClonal complexesChildhood pneumococcal conjugate vaccinationGerman National Reference CenterEarly vaccination periodHigher-valent vaccinesPneumococcal conjugate vaccinationNational Reference CenterConclusionsThe prevalenceConjugate vaccinationSerotype 23BPneumococcal diseaseChildhood vaccinationVaccination eraSurveillance periodSerogroups 23BackgroundThis studyReference centerVaccination formulationsPneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany
Imöhl M, Möller J, Reinert R, Perniciaro S, van der Linden M, Aktas O. Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infectious Diseases 2015, 15: 61. PMID: 25885764, PMCID: PMC4335684, DOI: 10.1186/s12879-015-0787-1.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseMeningitis casesPneumococcal meningitisQuellung reactionGerman National Reference CenterNeufeld Quellung reactionPre-PCV7 periodPneumococcal conjugate vaccinePost-vaccination periodCase mortality rateNational Reference CenterAntibiotic nonsusceptibilityIPD isolatesPneumococcal diseaseVaccination recommendationsVaccine recommendationsConjugate vaccineVaccine serotypesBroth microdilution methodVaccine effectsNationwide surveillancePneumococcal isolatesSerotype prevalenceReference centerMortality rate